Emergent BioSolutions announced that it has signed an indefinite-delivery, indefinite-quantity contract with the U.S. Department of State to establish a long-term, reliable, and stable supply chain for medical countermeasures that address chemical warfare agents. The contract is comprised of a five-year base period of performance along with five one-year option periods with a total contract value of a minimum of approximately $7M to a maximum of $100M over the contract's period of performance. Emergent will be supplying two of its current medical countermeasures addressing chemical threats; the Trobigard atropine sulfate/obidoxime chloride auto-injector, a drug-device combination product for emergency use in the event of nerve agent or organophosphate poisoning, and RSDL, which is intended to remove or neutralize chemical warfare agents and T-2 toxin from the skin.
https://thefly.com/landingPageNews.php?id=2872664
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.